top_10_image_2

Top Ten most popular articles on Pharmafile.com this week

pharmafile | October 30, 2020 | News story | Medical Communications  

The top ten news stories this week focus on COVID-19 studies, as new research has found that over 80% of COVID-19 patients in a recent study had a vitamin D deficiency while nearly 100,000 people are being infected with COVID-19 each day in England, according to a new study from Imperial College London.

In other news, IBM has partnered with Pfizer to design an artificial intelligence model to predict the eventual onset of neurological diseases – mainly Alzheimer’s – seven years before symptoms appear.

1. AstraZeneca’s COVID-19 vaccine generates immune response in both old and young participants

AstraZeneca’s much-hyped COVID-19 vaccine candidate, AZD1222, currently in development in partnership with the University of Oxford, has shown promising immune potential across a wide range of evaluated participants.

2. WHO warns regulators to consider all available evidence before approving remdesivir for COVID-19

The World Health Organization’s Chief Scientist Soumya Swaminathan has warned that experts and regulators assessing the use of Gilead’s remdesivir should consider all the available evidence before awarding marketing authorisation to treat COVID-19, and not just the FDA’s approval last week.

3. 80% of COVID-19 patients in study were vitamin D-deficient

New research has found that over 80% of COVID-19 patients in a recent study had a vitamin D deficiency.

4. IBM and Pfizer designing AI model to predict onset of neurological diseases

IBM has partnered with Pfizer to design an artificial intelligence model to predict the eventual onset of neurological diseases – mainly Alzheimer’s – seven years before symptoms appear.

5. Eli Lilly antibody treatment fails COVID-19 study

The US Government is putting an early end to clinical trials testing Eli Lilly’s antibody drug in COVID-19 patients.

6. Sanofi’s Dupixent shows strength at Phase 3 in eosinophilic esophagitis

Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of its co-primary and secondary endpoints in a study of its efficacy as a treatment of eosinophilic esophagitis (EoE) in patients at least 12 years old.

7. Nearly 100,000 people catching coronavirus every day in England, new study suggests

Nearly 100,000 people are being infected with COVID-19 each day according to a new study from Imperial College London.

8. Novartis announces positive Phase 2 data of rare renal disease therapy iptacopan

Novartis has announced positive Phase 2 interim analysis results for iptacopan, which is an investigational oral treatment for rare renal disease C3 glomerulopathy (C3G).

9. Novartis collaborates with Molecular Partners to develop therapies to use against COVID-19

Novartis and Molecular Partners AG have announced that they will develop, commercialise and manufacture Molecular’s anti-COVID-19 DARPin programme, which consists of two therapeutic candidates so far.

10. Bayer’s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer at risk of metastasis

NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of hormone-relapsed prostate cancer in adults at high-risk of developing metastasis.

Conor Kavanagh

Related Content

No items found

Latest content